[go: up one dir, main page]

WO1997040844A2 - Preparation d'extraits de plantes medicinales et ses composes a effet therapeutique et curatif - Google Patents

Preparation d'extraits de plantes medicinales et ses composes a effet therapeutique et curatif Download PDF

Info

Publication number
WO1997040844A2
WO1997040844A2 PCT/HU1997/000015 HU9700015W WO9740844A2 WO 1997040844 A2 WO1997040844 A2 WO 1997040844A2 HU 9700015 W HU9700015 W HU 9700015W WO 9740844 A2 WO9740844 A2 WO 9740844A2
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
extract
alcoholic
dry material
deoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU1997/000015
Other languages
English (en)
Other versions
WO1997040844A3 (fr
Inventor
János ARADI
Ferenc TÓTH
László FÉSU^'S
Szilvia TO^'KÉS
József TO^'ZSÉR
Károly Nagy
Iván URAY
Péter VÁRNAI
Irén MEZO^'
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU25195/97A priority Critical patent/AU2519597A/en
Publication of WO1997040844A2 publication Critical patent/WO1997040844A2/fr
Publication of WO1997040844A3 publication Critical patent/WO1997040844A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot

Definitions

  • the subject of the invention are medicinal plant extract preparation and its 5 compounds with therapeutic and curative anti-HIV and anti-apoptotic effects.
  • the Chelidonium majus, greater celandine is a well known herb, containing alkaloids, like chelidonine, chelerythrine, sanguinarine, protopine and also malic acid, citric acid, various salts and natural resins. The whole plant or the roots can be used as drug.
  • the alcoholic tincture or aqueous extract prepared from the plant is utilized as therapeutic agent for a long time.
  • the subject of the invention are medicinal plant based preparation and its compounds with therapeutic and curative anti-HIV and anti-apoptotic effects.
  • the preparations of this invention are characterized is by the followings: an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and any other compounds with known anti-HIV activity, preferably 2'-deoxy-3'-azidothimidine, or- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonine and/or chelerythrine and/or- sanguinarine or a mixture of these compounds with 2'-deoxy- -3'-azidothimidine- an alcoholic or aqueous extract of Chelidonium majus containing 0,5-99,9 % by weight of dry material and chelidonoine and/or chelerythrine and/or sanguinarine or any composition of these compounds with 2
  • the extract is prepared from the whole plant, or expediently from roots.
  • the diluted solution, which is formed on extraction, is evaporated, or if required in some cases, lyophilized.
  • the chelidonin, chelerythrine and sanguinarine may be isolated from the extract with preparative HPLC.
  • the effects of the products and compounds prepared according to the invention, and the mode of the preparation are shown in the following examples.
  • the dirt was removed from freshly picked roots of Chelidonium majus by washing and then dried partially at room temperature for 1-2 hours.
  • the roots were cut up to small pieces and 100 part (mass) cut root was mixed with 250 part (mass) of 96% alcohol.
  • the mixture was kept at room temperature in dark for 9 days and mixed up twice daily.
  • the solid was separated from the liquid, Extract I, containing 1,5% (w/w) dry material. This product was partially evaporated at 45°C in vacuum, then the residue was mixed with two parts (mass) of alcohol.
  • the mixture was filtrated.
  • the filtrate contains 6,2% (w/w) dry material,Extract II.
  • Example 3 The procedure was completed according to the Example N°. 1 but instead of the roots of Chelidonium majus the whole plant was utilized.
  • the dry material content of Extract I was 1,89% (w/w), the Extract II contained 6,5% by weight of dry material.
  • Example 3 The dry material content of Extract I was 1,89% (w/w), the Extract II contained 6,5% by weight of dry material.
  • Extract 1 and Extract II were evaporated in vacuum and the dry residue dissolved in DMSO in a final concentration of 100 mg/ml. These stock solutions were diluted with RPMI to get a final drug concentration of 100 ⁇ g/ml, and used in the treatment of infected cells. H9 cells were infected with HIV, and used in this study.
  • the drug solutions were added to the tissue culture (10 ⁇ cells/ml) at 1 or 6 hours prior infection, at the viral infection (0 time), 24 and 48 hours after infection.
  • the final drug concentration was 10 ⁇ g/ml at each addition.
  • the viruses were HIV-1 IIIB, produced by H9 cells (2xl0 5 IU/ml). The infection was completed in 2 hours at 37 °C, in CO2 incubator. When the infection of the cells was finished the cells were washed thoroughly with PBS the 0,5 million cells were seeded into 24-well plates and 2 ml medium was added into each well. The culturing was performed in CO2 incubator. The infected cell cultures were treated with Extract I and Extract II as mentioned above, appropriate control tissue cultures were also run, without drug.
  • Experiment A the extract is replaced with 1 ⁇ g/ml AZT; in Experiment B: 1 ⁇ l/ml AZT 1 ⁇ g/ml dry- material of extract II is combined.
  • the active compound and mixture is given to the tissue culture only once, after the viral infection.
  • the concentration of produced virions were determined on the 13th day of postinfection measuring the activity of reverse transcriptase in the cell free medium.
  • the reverse transcriptase activity was 19,9% compared to the control, in Experiment B this value was only 1,4%, representing 98,6% inhibition.
  • MT4 cells were infected with HIV-1 IIIB and the virus replication was inhibited using the following agents: chelidonine (I), chelerythrine (III), sanguinarine (II). The inhibition of virus replication was followed by determining the reverse transcriptase activity as above, on 5th and 8th day after viral infections.
  • control values were on 5th day: 153 824 cpm on 8th day: 56 266 cpm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une préparation à base d'extraits de plantes médicinales et ses composés à effet thérapeutique et curatif anti-VIH et anti-apoptotiques. Ladite préparation comporte un extrait alcoolique ou aqueux de Chélidonium majus contenant de 0,5 à 99,9 % en poids d'extrait sec; ou un extrait alcoolique ou aqueux de Chélidonium majus contenant de 0,5 à 99,9 % en poids d'extrait sec, plus tout autre composé connu pour son activité anti-VIH, de préférence de la 2'-désoxy-3'azidothimidine; ou de la chélidonine et/ou de la chélérythrine et/ou de la sanguinarine, ou leur mélange avec de la 2'-désoxy-3'azidothimidine; un extrait alcoolique ou aqueux de Chélidonium majus contenant de 0,5 à 99,9 % en poids d'extrait sec et de la chélidonine et/ou de la chélérythrine et/ou de la sanguinarine, ou tout mélange de ces composés avec de la 2'-désoxy-3'azidothimidine, lesdites préparations et/ou composés pouvant être complétés par des substances médicinales auxiliaires et additionnelles.
PCT/HU1997/000015 1996-04-26 1997-04-16 Preparation d'extraits de plantes medicinales et ses composes a effet therapeutique et curatif Ceased WO1997040844A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25195/97A AU2519597A (en) 1996-04-26 1997-04-16 Anti-hiv activity of medical plant extract preparation and its compounds with therapeutic and curative effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9601096A HUP9601096A2 (hu) 1996-04-26 1996-04-26 Anti-HIV-aktivitással rendelkező gyógynövényalapú gyógyászati és gyógyhatású készítmény,és vegyületek
HUP9601096 1996-04-26

Publications (2)

Publication Number Publication Date
WO1997040844A2 true WO1997040844A2 (fr) 1997-11-06
WO1997040844A3 WO1997040844A3 (fr) 1998-01-08

Family

ID=89993918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1997/000015 Ceased WO1997040844A2 (fr) 1996-04-26 1997-04-16 Preparation d'extraits de plantes medicinales et ses composes a effet therapeutique et curatif

Country Status (3)

Country Link
AU (1) AU2519597A (fr)
HU (1) HUP9601096A2 (fr)
WO (1) WO1997040844A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025365A (en) * 1997-03-25 2000-02-15 Arch Development Corp. Chelerythrine and radiation combined tumor therapy
CN111518158A (zh) * 2020-06-16 2020-08-11 北京赫尔默技术有限公司 一种抗手足口病化合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3128018A1 (de) * 1981-07-13 1983-04-07 Wassyl 1060 Wien Nowicky "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
CH660456A5 (de) * 1984-02-02 1987-04-30 Bupharm Ag Therapeutisches mittel zur bekaempfung von durch herpesviren verursachten infektionen.
EP0210815A3 (fr) * 1985-07-25 1988-04-20 Beecham Group Plc Dérivés d'acide 6-bêta-(alpha-oxyimino éthérifié)acylamino pénicillanique, leurs préparation et application

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025365A (en) * 1997-03-25 2000-02-15 Arch Development Corp. Chelerythrine and radiation combined tumor therapy
CN111518158A (zh) * 2020-06-16 2020-08-11 北京赫尔默技术有限公司 一种抗手足口病化合物及其制备方法与应用

Also Published As

Publication number Publication date
HU9601096D0 (en) 1996-06-28
HUP9601096A2 (hu) 1998-01-28
AU2519597A (en) 1997-11-19
WO1997040844A3 (fr) 1998-01-08

Similar Documents

Publication Publication Date Title
Kaplan et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis
EP1430903A1 (fr) Inhibiteurs du proteasome pour le traitement des infections virales
US8366935B2 (en) Phyllanthus extract
RU2518738C2 (ru) Композиции для лечения заболеваний верхних дыхательных путей и симптомокомплекса гриппа
CA2066155A1 (fr) Agent antiviral pour le virus de l'immunodeficience humaine
Palomino et al. Screening of South American plants against human immunodeficiency virus: preliminary fractionation of aqueous extract from Baccharis trinervis
CA2009505C (fr) Inhibiteur de l'adsorption du virus de l'herpes
EP0199429B1 (fr) Préparation d'un médicament pour traiter l'hépatite virale
WO2017013568A1 (fr) Composition anti-herpétique et formulation pharmaceutique anti-herpétique
WO1997040844A2 (fr) Preparation d'extraits de plantes medicinales et ses composes a effet therapeutique et curatif
KR20000069296A (ko) 항바이러스 활성을 갖는 살비아 종의 추출물
US6156349A (en) Method of treating HIV infection with suppository containing mammalian liver extract
RU2182828C1 (ru) Композиция, обладающая антивич и антигерпесной активностью
CN110269854A (zh) 桑根酮c的医药新用途
WO1990003172A2 (fr) Acides biliaires de traitement d'infections virales
DE69610045T2 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
JP3002700B2 (ja) 抗エイズウイルス剤
KR100668689B1 (ko) 라이노바이러스에 대한 항바이러스 조성물
AU592851B2 (en) Transdermal formulations
RU2244554C1 (ru) Средство для лечения вирусного гепатита с
US5283239A (en) Inhibitor of herpesvirus absorption
JPS6137731A (ja) グアバ葉エキスを有効成分とする経口糖尿病薬
ES2761429T3 (es) Composición farmacéutica antiviral, que contiene un extracto de Juncus acutus
RU1805967C (ru) Биологически активное вещество против вируса СПИД
JPH0474333B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97538679

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase